Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy
It is feasible to measure longitudinal PROs in patients who receive CART therapy. This study will inform future studies in evaluating the patient perspective on CART therapy.
Authors
- Mark N. Levine (ORCID: https://orcid.org/0000-0003-1288-0773)
- Amaris Balitsky (ORCID: https://orcid.org/0000-0002-2831-9107)
- Graeme Fraser
- Gregory R. Pond (ORCID: https://orcid.org/0000-0003-1033-0882)
- Ronan Foley (ORCID: https://orcid.org/0009-0005-9817-8011)
- GA Davies
- Tom Kouroukis
- RM Meyer
Institutions
- Juravinski Cancer Centre (CA)
- Ontario Clinical Oncology Group (CA)
- Institute of Cancer Research (CA)
- Hamilton Health Sciences (CA)
- McMaster University (CA)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-08-09
- DOI
- https://doi.org/10.1186/s12885-024-12574-2
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.57